Targeted therapies to join chemo as oncology treatment backbone
In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens…
03 Mar 2026
Europe’s pharma trade with the US remains critical despite tariff turmoil
US government policies of Most Favored Nation (MFN) and tariffs threaten to disrupt Europe’s pharmaceutical trade, but while European countries explore alternative markets in Asia, it may be difficult for…
02 Mar 2026
How America’s former steel heartland secured a $3.5bn Eli Lilly facility
Surveying Lehigh Valley’s historical industrial sites along the Lehigh River evokes a bygone era when the region was home to one of the world’s largest steel producing hubs. Today, recent…
27 Feb 2026
Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new guidance documents. These documents include the Rare Disease Evidence Pathway…
27 Feb 2026
Rare disease developers applaud clarity in FDA guidance
Stakeholders in the rare disease development community say that new guidance documents, released by the US Food and Drug Administration (FDA) over the past year, have delivered much-needed clarity on…
26 Feb 2026
Nonprofit models support strategic boldness to develop gene therapies for rare diseases
Non-profit organisations play a crucial role in supporting rare disease therapy development and rescuing shelved programmes, where commercial interest may be weak. Gene therapies represent a fundamental approach to tackling…
23 Feb 2026
Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
With the full-year 2025 earnings season coming to a close, certain sectors in healthcare performed strongly against the industry average. In the latest GlobalData Healthcare Podcast, pharmaceutical editor Robert Barrie…